19-Nov-2018
Peoples Dispatch
Multinational corporations are suing countries for using generic versions of life saving medicines.
12-Nov-2018
Don’t trade our lives away
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
8-Nov-2018
The Guardian.pe.ca
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
9-Oct-2018
European Pharmaceutical Manufacturer
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
5-Oct-2018
Financial Post
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
28-Aug-2018
Pharmaceutical Commerce
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.
19-Jun-2018
Sydney Morning Herald
Trade Minister Steven Ciobo has promised to take a hard line with Europe on the question of cheap medicines and his counterpart Cecilia Malmström foresees “difficult” negotiations over Australian producers using European names such as "parmesan".
11-Apr-2018
MSF Access Campaign
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.